Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

On Wednesday February 28, 2024, Lyell Immunopharma Reported Q4 Adjusted. EPS $(0.17) Beats $(0.23) Estimate, Sales $13.00K Down From $48.39M YoY

Author: Happy Mohamed | February 29, 2024 04:26pm
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. The company reported $13.00 thousand in sales this quarter. This is a 99.97 percent decrease over sales of $48.39 million the same period last year.

Posted In: LYEL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist